Table 1
Published literature on the efficacy, safety, and tolerability of tegaserod
| Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms of IBS in patients with abdominal pain, bloating, and constipation | Aliment Pharmacol Ther2001;:–66 |
| Safety and tolerability of tegaserod in patients with IBS and symptoms of diarrhoea | Am J Gastroenterol2002;:–81 |
| Long term safety of tegaserod in patients with constipation-predominant IBS | Aliment Pharmacol Ther2002;:–8 |
| A randomised, double blind, placebo controlled trial of tegaserod in female patients suffering from IBS with constipation | Aliment Pharmacol Ther2002;:–88 |
| Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects | Am J Gastroenterol2002;:–27 |
| An Asian-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with IBS | Gut2003;:–6 |
